Finally, there's Onyx, a larger, $6.2 billion company with three products on the market treating five different indications. With over $1 billion in sales so far, things look bright for this biotech, which has a potential $5 billion breast cancer treatment in the works. With no new approvals expected soon, Cramer said investors can also wait for this stock to offer a good entry point before buying in.
Executive Decision: Jack Fonss
In the "Executive Decision" segment, Cramer continued his crusade against highly-leveraged ETFs by sitting down with Jack Fonss, CEO of AccuShares, a company hoping to offer investors some clarity on what these complex financial instruments are all about.Fonss said that while the ETF market started out with good intentions, it has involved into a mess that no investor can understand. He said many of the levered ETFs, while marketed as great for professional traders, are really good for no one because they rebalance daily and often produce extremely poor results. Fonss said that in a market that is only going up or only going down, some of these instruments may make money, but in a normal market with both ups and downs they simply don't work. Compounding the problem is there are now some 15,000 ETF products and many investors aren't doing their due diligence to understand what the funds actually do. The US Natural Gas ETF (UNG), for example, doesn't invest in natural gas, it invests in natural gas futures that do not trade in tandem with the commodity as individual investors may think. Fonss' company, AccuShares, hopes to solve this problem by offering funds that stick to what he described as the three best practices for ETFs: holding only liquid assets, holding them consistently and doing so in a transparent manner. Cramer lauded Fonss for his efforts in helping individual investors and vowed to have him return as soon as AccuShares initial funds are available for trading.